Decision Resources to Publish Reports Assessing Unmet Need and Commercial
Opportunities in the Cardiovascular and Metabolic Diseases Drug Markets
BURLINGTON, Mass., Dec. 17, 2013
BURLINGTON, Mass., Dec. 17, 2013 /PRNewswire/ -- Decision Resources, one of
the world's leading research and advisory firms for pharmaceutical and
healthcare issues, will soon publish analysis of unmet need and commercial
opportunities for developers of drugs that treat cardiovascular and metabolic
Some of the key findings in these reports include the following:
oSurveyed U.S. and European primary care physicians agree that increased
weight-loss efficacy is one of the attributes that most influences their
decisions regarding prescribing in obesity. Clinical data and the opinions
of interviewed thought leaders indicate that phentermine (UCB's Ionamin,
generics), Vivus's Qsymia, Orexigen/Takeda's Contrave, Novo Nordisk's
Victoza and Zafgen's beloranib have advantages on this attribute over
sales-leading orlistat (Roche's Xenical, generics; GlaxoSmithKline's
oSurveyed U.S. and European pulmonologists agree that improved long-term
survival is one of the attributes that most influences their decisions
regarding prescribing in pulmonary arterial hypertension. Clinical data
and the opinions of interviewed thought leaders indicate that
Actelion/Nippon Shinyaku's Opsumit has advantages on this attribute over
sales-leading Actelion's Tracleer.
oThe availability of generic metformin and sulfonylureas for the treatment
of type 2 diabetes will continue to have a substantial influence on
physicians' prescribing and payers' formulary coverage. The struggles of
managed care organizations (MCOs) to contain healthcare costs often lead
them to encourage use of generics in early lines of therapy. New classes
of antidiabetic agents face considerable reimbursement hurdles,
particularly if they are expensive. Emerging therapies that are
reformulations of already-available molecules, with limited advantages
beyond delivery, will likely face significant market access hurdles and
stiff MCO resistance to formulary inclusion, if priced at a premium to
their parent molecules.
These findings can be found in the following reports which will publish in the
oObesity: What Key Attributes Will Drive Formulary Inclusion and
Prescribing of Current and Emerging Agents?
oWhat Key Attributes Will Drive Pulmonologists to Prescribe and Payers to
Reimburse Novel PAH Agents?
oNovel SGLT-2 Inhibitors, Next-Generation Once-Weekly GLP-1 Receptor
Agonists, and New Insulins Appear on the Horizon for Type 2 Diabetes: What
Market Access Challenges Will These New Therapies Face?
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market
research publications, advisory services and consulting designed to help
clients shape strategy, allocate resources and master their chosen markets.
Decision Resources is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources Group at
All company, brand, or product names contained in this document may be
registered trademarks of their respective holders.
SOURCE Decision Resources
Contact: Decision Resources Group: Christopher Comfort, 781-993-2597,
Press spacebar to pause and continue. Press esc to stop.